ST101 Selected for Clinical Development
ANTWERP, Belgium – December 9, 2025 – Spica Therapeutics (“Spica”), a biotechnology company pioneering precision macrophage-targeted therapies, today announced the nomination of ST101 as its first clinical development candidate. ST101 is a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumor-associated macrophages (TAMs). The company has initiated CMC activities to support upcoming IMPD enabling […]
Spica Therapeutics Secures €1M VLAIO Grant
Spica Therapeutics Secures €1M VLAIO Grant Antwerp, Belgium – 27 August, 2025 – Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.0 million grant from Flanders Innovation & Entrepreneurship (VLAIO). This two-year grant will accelerate the […]
Spica Therapeutics Closes €10M Seed Round
Spica Therapeutics Closes €10M Seed Round The financing round was co-led by Bioqube Ventures and Flanders Future Tech Fund (FFTF, managed by the Flemish investment company PMV), with participation from Qbic. Spica entered a strategic collaboration with Vrije Universiteit Brussel (VUB) and VIB, a leading life sciences research institute to leverage world-class expertise across Belgium. […]
Spica Therapeutics Emerges from Stealth
Bioqube Ventures Unveils Spica Therapeutics to Pioneer Macrophage-Subset Targeted Therapies Innovating macrophage-targeted therapeutics across multiple therapeutic areas Proprietary functional macrophage fingerprinting technology identifies disease-relevant macrophage subsets Strengthened by the appointments of James Rush as CEO and Jim Van Heusden as Chairman Backed by Bioqube Ventures’ venture creation model Brussels, Belgium, January 9, 2025 – Spica […]